Healthcare provider profile · identity verified

Thomas John Demarco, MD

Internal Medicine · SMYRNA, GA · NPI 1093825846

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	196	31
Atorvastatin Calcium	Atorvastatin Calcium	149	29
Losartan Potassium	Losartan Potassium	128	21
Amlodipine Besylate	Amlodipine Besylate	115	23
Tamsulosin Hcl	Tamsulosin Hcl	106	22
Metoprolol Succinate	Metoprolol Succinate	88	17
Gabapentin	Gabapentin	80	25
Donepezil Hcl	Donepezil Hcl	78	16
Metoprolol Tartrate	Metoprolol Tartrate	74	17
Furosemide	Furosemide	68	18
Lisinopril	Lisinopril	68	13
Escitalopram Oxalate	Escitalopram Oxalate	66	13
Spironolactone	Spironolactone	66	18
Eliquis	Apixaban	64	18
Omeprazole	Omeprazole	64	13
Pantoprazole Sodium	Pantoprazole Sodium	64	21
Trazodone Hcl	Trazodone Hcl	58	16
Tramadol Hcl	Tramadol Hcl	56	18
Rosuvastatin Calcium	Rosuvastatin Calcium	54	suppressed
Alprazolam	Alprazolam	52	13
Carvedilol	Carvedilol	52	16
Duloxetine Hcl	Duloxetine Hcl	52	suppressed
Memantine Hcl	Memantine Hcl	51	13
Quetiapine Fumarate	Quetiapine Fumarate	50	17
Lorazepam	Lorazepam	44	27
Sertraline Hcl	Sertraline Hcl	43	11
Valsartan	Valsartan	43	suppressed
Metformin Hcl	Metformin Hcl	42	11
Finasteride	Finasteride	37	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	36	11
Montelukast Sodium	Montelukast Sodium	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	12
Methenamine Hippurate	Methenamine Hippurate	31	suppressed
Potassium Chloride	Potassium Chloride	31	12
Oxycodone Hcl	Oxycodone Hcl	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Pregabalin	Pregabalin	28	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	26	14
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Levetiracetam	Levetiracetam	25	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	11
Budesonide Dr	Budesonide	23	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Methylprednisolone	Methylprednisolone	23	15
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	19
Diltiazem Hcl	Diltiazem Hcl	21	suppressed
Glipizide Er	Glipizide	21	suppressed
Meloxicam	Meloxicam	21	suppressed
Memantine Hcl Er	Memantine Hcl	20	suppressed
Risperidone	Risperidone	20	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Famotidine	Famotidine	19	suppressed
Fentanyl	Fentanyl	19	suppressed
Morphine Sulfate	Morphine Sulfate	19	19
Levofloxacin	Levofloxacin	18	17
Clindamycin Hcl	Clindamycin Hcl	17	11
Folic Acid	Folic Acid	17	suppressed
Rivastigmine	Rivastigmine Tartrate	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Haloperidol	Haloperidol	16	13
Loperamide	Loperamide Hcl	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Prednisone	Prednisone	14	suppressed
Calcitriol	Calcitriol	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Phenobarbital	Phenobarbital	13	suppressed
Temazepam	Temazepam	13	suppressed
Amoxicillin	Amoxicillin	12	11
Baclofen	Baclofen	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Tiadylt Er	Diltiazem Hcl	12	suppressed
Azelastine-Fluticasone	Azelastine/Fluticasone	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error